Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05771480 · ClinicalTrials.gov registry record · Phase 3
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
A Phase 3 study of Biliary Tract Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
- 20
- Study locations
NCT05771480 is a Phase 3 study of Biliary Tract Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 142 participants, below the 235-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05771480, a Phase 3 study of Biliary Tract Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- DRUG Gemcitabine + cisplatin
- DRUG Gemcitabine + carboplatin
- DRUG Gemcitabine monotherapy
- DRUG Gemcitabine + oxaliplatin
Study Locations (20)
Other
- Research Site - Clichy
- Research Site - Dijon
- Research Site - Montpellier
- Research Site - Villejuif
- Research Site - Chemnitz
- Research Site - Hanover
- Research Site - Castelfranco Veneto
- Research Site - Foggia
- Research Site - Palermo
- Research Site - Pisa
- Research Site - Rozzano
- Research Site - Chūōku
- Research Site - Kanazawa
- Research Site - Kashiwa
- Research Site - Kyoto
- Research Site - Osaka
Alabama
- Research Site - Mobile
California
- Research Site - Orange
District of Columbia
- Research Site - Washington D.C.
Oregon
- Research Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2026-03-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05771480
The ClinicalTrials.gov registry entry for NCT05771480 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (40% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Biliary Tract Cancer appearing as the primary indexed condition, and to 5 interventions - of which Durvalumab is the first listed.
NCT05771480 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT05771480 about?
NCT05771480 is a clinical study titled "Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)". A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
What is the current status of trial NCT05771480?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2023-08-16. Estimated completion is 2026-03-17.
What conditions does trial NCT05771480 study?
This clinical trial studies the following conditions: Biliary Tract Cancer.
What interventions are being tested in trial NCT05771480?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Gemcitabine + cisplatin (DRUG), Gemcitabine + carboplatin (DRUG), Gemcitabine monotherapy (DRUG), Gemcitabine + oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT05771480?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05771480 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RECRUITING · Phase 3
-
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
RECRUITING · Phase 3
-
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
RECRUITING · Phase 3
-
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.